Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

Marketing Automation for Pharma - Sign-up for your free webinar

Marketing Automation for Pharma

With Pharma Marketers increasingly being asked to do more with fewer resources, Marketing Automation is a key area that needs to be explored. Find out how it could help you...

Blue Latitude Health

- PMLiVE

It’s a beautiful day in the neighbourhood: The importance of data

Clinical trial data is vital for clinicians practicing evidence-based medicine, but even more compelling can be real-world data gathered from local real-world patients

- PMLiVE

Quality Standards – are we making the most of them?

As the UK health service enters a new chapter, NICE begins developing best practice guidelines

- PMLiVE

Janssen’s first-in-class diabetes drug Invokana wins US approval

Will be first SGLT2 inhibitor to reach the market in the States

- PMLiVE

US MM&M Awards– last call for entries

Reminder to enter MM&M Awards honouring creativity and marketing effectiveness in healthcare

- PMLiVE

Pfizer’s Bosulif gets conditional green light for CML in Europe

Follows US approval last year

- PMLiVE

Novartis says Indian Glivec verdict “discourages innovation”

Country's Supreme Court denies the cancer drug patent protection

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

Boehringer – Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

Biogen Idec building

Biogen Idec’s Tecfidera approved in US

Green light from FDA closely follows MS drug's European approval

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

Eisai expands into Russia with Halaven launch

Breast cancer drug will be followed by epilepsy portfolio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links